Editor-in-Chief: Alex A. Adjei, MD, PhD, FACP
ISSN: 1556-0864
Online ISSN: 1556-1380
Frequency: 12 issues / year
Ranking: Oncology 26/202
Respiratory System 5/53
Impact Factor: 5.800
Editor's Choice

Four manuscripts that provide information on different aspects of thoracic oncology are highlighted in the February issue of JTO. The first manuscript, Racial diversity of actionable mutations in non-small cell lung cancer, by Bollig-Fischer et al. provides information on racial differences in actionable mutations in NSCLC in the US, and is accompanied by an excellent editorial from Dr Tetsuya Mitsudomi. The second manuscript by Um et al, addresses the important issue of mediastinial nodal staging for the work-up of NSCLC - Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-small Cell Lung Cancer. Um et al. Weiss et al provide critical information on thymoma in The Impact of Thymoma Histotype on Prognosis in a Worldwide Database. Weis et al. Finally, Gainor et al present a series of patients with ALK rearranged NSCLC who developed leptomeningeal disease on crizotinib and responded to alectinib- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib. Gainor et al. Alex A. Adjei, MD, PhD, Editor-in-Chief

Actions
View
  • Open Access
  • Free Access
  • Purchase Access
  • Partial Access
Actions
View
Login

Quick Poll

For coverage of this subject, please see Boland JM et al, J Thorac Oncol, 8: 574 -581, 2013

A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
 Submit
 Clear
 Results
Foreign Language Editions

JTO is proud to present translations of its content into French and Chinese. We sincerely thank  Jean-Louis Pujol, Wu Yilong, and Tony Mok for their work on the French and Chinese editions.  

French, Selected Articles

French JTO, Vol 1 Issue 1

French JTO, Vol 1 Issue 2

French JTO, Vol 1 Issue 3

 

Chinese, Selected Articles

Chinese JTO, Vol 2 Issue 2

 

Call for Videos
JTO accepts videos as supplemental content to articles. Submission guidelines online.
Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.